PMID- 31380263
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 9
DP  - 2019
TI  - CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential 
      Therapeutic Target.
PG  - 557
LID - 10.3389/fonc.2019.00557 [doi]
LID - 557
AB  - Objective: Chemoresistance is a major challenge in epithelial ovarian cancer 
      (EOC) treatment. Chromatin target of protein arginine methyltransferase (CHTOP) 
      was identified as a potential biomarker in chemoresistant EOC cell lines using 
      label-free LC-MS/MS quantitative proteomics. Thus, the aim of this study is to 
      investigate the role of CHTOP in chemoresistant EOC and the underlying mechanism. 
      Methods: The expression of CHTOP in human ovarian cancer cells and tissues was 
      detected using immunofluorescence (IF), western blot (WB), and 
      immunohistochemistry (IHC), respectively. Flow cytometry and TUNEL assay were 
      employed to detect the effect of CHTOP knockdown (KD) in chemoresistant EOC cell 
      apoptosis, while colony and sphere formation assays were used to evaluate its 
      effect on cell stemness. The association of CHTOP with cell metastasis was 
      determined using Matrigel invasion and wound-healing assays. Results: The higher 
      level expression of CHTOP protein was found in chemoresistant EOC cells as 
      compared to their sensitive parental cells or normal epithelial ovarian cells. 
      Results from IHC and bioinformatic analysis showed CHTOP was highly expressed in 
      human ovarian cancer tissues and associated with a poor progression-free survival 
      in patients. In addition, CHTOP KD significantly enhanced cisplatin-induced 
      apoptosis, reduced the stemness of chemoresistant EOC cells, and decreased their 
      metastatic potential. Conclusion: Our findings suggest that CHTOP is associated 
      with apoptosis, stemness, and metastasis in chemoresistant EOC cells and might be 
      a promising target to overcome chemoresistance in EOC treatment.
FAU - Feng, Xiaojie
AU  - Feng X
AD  - Department of Gynaecological Oncology, Henan Cancer Hospital, Zhengzhou, China.
AD  - Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
AD  - St. George and Sutherland Clinical School, University of New South Wales Sydney, 
      Sydney, NSW, Australia.
FAU - Bai, Xupeng
AU  - Bai X
AD  - Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
AD  - St. George and Sutherland Clinical School, University of New South Wales Sydney, 
      Sydney, NSW, Australia.
FAU - Ni, Jie
AU  - Ni J
AD  - Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
AD  - St. George and Sutherland Clinical School, University of New South Wales Sydney, 
      Sydney, NSW, Australia.
FAU - Wasinger, Valerie C
AU  - Wasinger VC
AD  - Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, 
      University of New South Wales Sydney, Sydney, NSW, Australia.
AD  - School of Medical Science, University of New South Wales Sydney, Sydney, NSW, 
      Australia.
FAU - Beretov, Julia
AU  - Beretov J
AD  - Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
AD  - St. George and Sutherland Clinical School, University of New South Wales Sydney, 
      Sydney, NSW, Australia.
AD  - Anatomical Pathology, NSW Health Pathology, St. George Hospital, Kogarah, NSW, 
      Australia.
FAU - Zhu, Ying
AU  - Zhu Y
AD  - Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
AD  - St. George and Sutherland Clinical School, University of New South Wales Sydney, 
      Sydney, NSW, Australia.
FAU - Graham, Peter
AU  - Graham P
AD  - Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
AD  - St. George and Sutherland Clinical School, University of New South Wales Sydney, 
      Sydney, NSW, Australia.
FAU - Li, Yong
AU  - Li Y
AD  - Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
AD  - St. George and Sutherland Clinical School, University of New South Wales Sydney, 
      Sydney, NSW, Australia.
AD  - School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20190627
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC6660285
OTO - NOTNLM
OT  - CHTOP
OT  - apoptosis
OT  - chemoresistance
OT  - metastasis
OT  - ovarian cancer
OT  - stemness
EDAT- 2019/08/06 06:00
MHDA- 2019/08/06 06:01
PMCR- 2019/01/01
CRDT- 2019/08/06 06:00
PHST- 2019/03/08 00:00 [received]
PHST- 2019/06/07 00:00 [accepted]
PHST- 2019/08/06 06:00 [entrez]
PHST- 2019/08/06 06:00 [pubmed]
PHST- 2019/08/06 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2019.00557 [doi]
PST - epublish
SO  - Front Oncol. 2019 Jun 27;9:557. doi: 10.3389/fonc.2019.00557. eCollection 2019.